Drug Profile


Alternative Names: Anti-GD3 monoclonal antibody - Life Science Pharmaceuticals; KM-871; KM-8871; KW-2871

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko Kirin; Life Science Pharmaceuticals; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 01 Dec 2014 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV) (Life Science Pharmaceuticals 2014 pipeline)
  • 01 Dec 2014 Discontinued - Phase-II for Malignant melanoma (Combination therapy) in USA (IV) (Life Science Pharmaceuticals 2014 pipeline)
  • 29 Sep 2011 Phase-II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top